◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › M › MESO

Mesoblast Ltd (MESO) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-12

Mesoblast Ltd (MESO) operates in the BIOTECHNOLOGY industry and is headquartered in Melbourne, Australia with about 108 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2026-06-30, MESO reported $121M in revenue and ($58M) in net income.

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.

Interactive charts & full statements → Open the MESO valuation workbench →

MESO Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2026-06-30	2025-06-30	2024-06-30	2023-06-30	2022-06-30	2021-06-30	2020-06-30	2019-06-30	2018-06-30	2017-06-30	2016-06-30	2015-06-30	2014-06-30	2013-06-30	2012-06-30	2011-06-30	2010-06-30	2009-06-30	2008-06-30	2007-06-30
Total Revenue	$120M	$121M	$17M	$6M	$8M	$10M	$7M	$32M	$17M	$17M	$2M	$43M	$24M	$26M	$29M	$38M	$121M	$0M	$1M	$1M	$2M
Gross Profit	$96M	$102M	$12M	($35M)	($47M)	($53M)	($78M)	($49M)	($58M)	$12M	($10M)	$13M	$0M	$1M	$8M	$38M	$121M	$0M	$1M	$1M	$2M
Gross Margin %	80.0%	84.1%	70.2%	-595.9%	-632.2%	-522.6%	-1049.8%	-153.4%	-349.5%	68.2%	-400.2%	30.0%	-0.1%	2.1%	26.1%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Operating Income (EBIT)	($52M)	($52M)	($62M)	($84M)	($69M)	($81M)	($109M)	($75M)	($80M)	($77M)	($90M)	($56M)	($113M)	($72M)	($60M)	($49M)	$94M	($10M)	($9M)	($8M)	($7M)
Operating Margin %	-42.8%	-42.6%	-363.1%	-1425.7%	-923.7%	-789.1%	-1463.2%	-232.8%	-479.6%	-446.0%	-3733.1%	-131.3%	-477.5%	-278.6%	-208.7%	-127.3%	77.5%	-188851.8%	-1058.6%	-872.7%	-417.6%
Net Income	($58M)	($58M)	($102M)	($88M)	($82M)	($91M)	($99M)	($78M)	($90M)	($35M)	($77M)	($4M)	($119M)	($81M)	($62M)	($71M)	$91M	($15M)	($12M)	($10M)	($9M)
Net Margin %	-47.8%	-47.8%	-593.9%	-1490.3%	-1091.7%	-894.6%	-1325.2%	-242.4%	-537.0%	-203.5%	-3184.7%	-9.7%	-502.6%	-311.6%	-214.2%	-185.9%	74.9%	-268743.5%	-1379.3%	-1106.0%	-519.7%
EBITDA	($45M)	($43M)	($74M)	($56M)	($59M)	($77M)	($85M)	($69M)	($85M)	($75M)	($87M)	($28M)	($90M)	($67M)	($59M)	($48M)	$92M	($11M)	($9M)	($8M)	($7M)
Earnings Per Share (EPS)	$-0.44	$-0.45	$-0.85	$-0.89	$-0.98	$-1.34	$-1.63	$-1.47	$-1.82	$-0.38	$-1.43	$-0.08	$-2.22	$-1.51	$-1.15	$-1.32	$1.69	$-0.27	$-0.23	$-0.19	$-0.16
Shares Outstanding (M)	130M	129M	121M	99M	84M	68M	61M	53M	49M	93M	54M	54M	54M	54M	54M	54M	54M	54M	54M	54M	54M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MESO Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$34M	$34M	$26M	$26M	$7M	$7M	$2M	$2M
Gross Profit	$49M	$49M	($1M)	($1M)	($16M)	($16M)	($2M)	($2M)
Gross Margin %	143.2%	143.2%	-4.7%	-4.7%	-231.1%	-231.1%	-107.8%	-107.8%
Operating Income (EBIT)	$46M	($20M)	($39M)	($39M)	($34M)	($34M)	($21M)	($21M)
Operating Margin %	133.8%	-59.5%	-150.2%	-150.2%	-489.5%	-489.5%	-1306.7%	-1306.7%
Net Income	($9M)	($9M)	($20M)	($20M)	($27M)	($27M)	($24M)	($24M)
Net Margin %	-25.2%	-25.2%	-78.2%	-78.2%	-386.0%	-386.0%	-1518.8%	-1518.8%
EBITDA	($10M)	($10M)	($13M)	($13M)	($20M)	($20M)	($9M)	($9M)
Earnings Per Share (EPS)	$-0.07	$-0.07	$-0.16	$-0.16	$-0.21	$-0.21	$-0.21	$-0.21
Shares Outstanding (M)	130M	130M	129M	129M	127M	127M	114M	114M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MESO Free Cash Flow History

Cash flow	TTM → 2026-06-30	2026-06-30	2025-06-30	2024-06-30	2023-06-30	2022-06-30	2021-06-30	2020-06-30	2019-06-30	2018-06-30	2017-06-30	2016-06-30	2015-06-30	2014-06-30	2013-06-30	2012-06-30	2011-06-30	2010-06-30	2009-06-30	2008-06-30	2007-06-30
Cash from Operations (CFO)	($44M)	($44M)	($50M)	($48M)	($63M)	($66M)	($107M)	($56M)	($58M)	($75M)	($95M)	($88M)	($122M)	($82M)	($54M)	($72M)	$108M	($10M)	($9M)	($6M)	($9M)
Capital Expenditures (CapEx)	$1M	$1M	$1M	$0M	$0M	$0M	$2M	$2M	$0M	$0M	$0M	$1M	$3M	$38M	$3M	$3M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($45M)	($45M)	($51M)	($49M)	($64M)	($66M)	($108M)	($59M)	($58M)	($75M)	($96M)	($89M)	($124M)	($120M)	($57M)	($75M)	$108M	($10M)	($9M)	($6M)	($9M)
FCF Margin %	-37.3%	-37.0%	-294.7%	-826.7%	-847.7%	-646.5%	-1452.9%	-182.3%	-347.3%	-433.7%	-3971.1%	-209.0%	-523.9%	-461.0%	-197.7%	-195.5%	89.1%	-177177.7%	-1056.2%	-692.8%	-552.9%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MESO Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($9M)	($4M)	($16M)	($15M)	($17M)	($13M)	($10M)	($10M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($9M)	($4M)	($16M)	($15M)	($17M)	($13M)	($10M)	($10M)
FCF Margin %	-27.5%	-13.0%	-61.1%	-59.4%	-240.8%	-182.4%	-645.2%	-657.8%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MESO Balance Sheet History

Balance sheet	2026-06-30	2026-06-30	2025-06-30	2024-06-30	2023-06-30	2022-06-30	2021-06-30	2020-06-30	2019-06-30	2018-06-30	2017-06-30	2016-06-30	2015-06-30	2014-06-30	2013-06-30	2012-06-30	2011-06-30	2010-06-30	2009-06-30	2008-06-30	2007-06-30
Total Assets	$773M	$773M	$785M	$669M	$669M	$662M	$745M	$734M	$652M	$692M	$656M	$684M	$1.0B	$899M	$884M	$720M	$763M	$40M	$27M	$28M	$21M
Cash & Cash Equivalents	$103M	$47M	$161M	$63M	$71M	$60M	$137M	$129M	$50M	$38M	$46M	$22M	$28M	$4M	$8M	$207M	$263M	$32M	$17M	$14M	$12M
Total Liabilities	$205M	$205M	$187M	$189M	$168M	$165M	$163M	$184M	$171M	$146M	$139M	$156M	$409M	$328M	$253M	$242M	$247M	$2M	$1M	$2M	$1M
Total Debt (Short + Long-Term)	$122M	$122M	$125M	$117M	$113M	$100M	$97M	$93M	$81M	$119M	$0M	$0M	$0M	$6M	$0M	$3M	$0M	$0M	$0M	$0M	$0M
Total Shareholders' Equity	$568M	$568M	$597M	$480M	$502M	$497M	$581M	$549M	$481M	$546M	$517M	$528M	$609M	$572M	$630M	$479M	$516M	$38M	$26M	$26M	$21M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive MESO viewer.

Other Companies in BIOTECHNOLOGY

ZBIO · Zenas BioPharma, Inc. Common Stock — $2 billion
VCEL · Vericel Corp Ord — $2 billion
ADMA · ADMA Biologics Inc — $2 billion
AGIO · Agios Pharm — $2 billion
RAPP · Rapport Therapeutics, Inc. Common Stock — $2 billion
GHRS · GH Research PLC — $2 billion
COAG · Hemab Therapeutics Holdings, Inc. Common Stock — $2 billion
ZYME · Zymeworks Inc. Common Stock — $2 billion

← MESH All “M” companies MESR →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.